In this article, we will take a look at the 10 Stocks Under $10 Analysts Believe Could Soar 200%.
Stocks trading below $10 have always attracted investors looking for outsized returns. The appeal is easy to understand: a stock rising from $5 to $15 delivers a 200% gain, meaning the investment triples in value. However, a low share price does not automatically mean a company is cheap.
One useful piece of market trivia is that share price and company size are not the same thing. A stock trading at $6 can still represent a multibillion-dollar business if the company has hundreds of millions of shares outstanding. That is why investors searching for the best stocks under $10 should also examine market capitalization, revenue growth, profitability, debt, cash flow, and long-term business prospects.
The companies featured in this article are not small penny stocks. Each has a market capitalization of more than $2 billion and carries a consensus analyst price target suggesting at least 200% upside.
Small-Cap Stocks Are Gaining Momentum
The search for 10 stocks under $10 that could soar 200% comes as smaller companies begin outperforming the broader U.S. stock market.
On July 2, Dominic Pappalardo, Chief Multi-Asset Strategist at Morningstar Wealth, said small-cap stocks could continue delivering above-market returns because their valuations remain attractive compared with large-cap shares.
During 2026, the Morningstar U.S. Small Cap Market Index gained 14%, outperforming the 10.7% increase recorded by the broader Morningstar U.S. Market.
This performance is notable because U.S. small-cap stocks have generally lagged their mid-cap and large-cap peers over the past 15 years. That prolonged underperformance has left many smaller companies trading at discounted valuations, creating potential opportunities for investors looking for undervalued stocks under $10.
The small-cap rally has continued despite a volatile year shaped by geopolitical tensions, including the Iran-U.S. conflict. Latin American stocks have also performed well since the beginning of the war, supported partly by the region’s exposure to oil and other commodities.
Small Caps May Offer Better Diversification
Pappalardo also pointed to diversification as another reason investors may consider small-cap stocks.
Although the S&P 500 includes around 500 companies, approximately 40% of the index is concentrated in its 10 largest holdings. This means a relatively small group of mega-cap companies can have an enormous influence on the performance of the broader market.
Small-cap indexes are generally less concentrated. Their performance is spread across a wider range of industries, including healthcare, financial services, industrials, energy, consumer products, and technology.
This broader exposure could appeal to investors who believe the market has become too dependent on a handful of large technology companies. It may also create opportunities to find high-upside stocks under $10 that are overlooked by investors focused primarily on the biggest names on Wall Street.
Why Stocks Under $10 Can Produce Large Returns
Low-priced stocks can generate dramatic percentage gains because even a relatively small dollar increase can translate into a large return.
For example, a stock rising from $3 to $6 doubles in value. If it reaches $9, it produces a 200% gain. However, the same mathematics also works in reverse. A decline from $6 to $3 results in a 50% loss.
That is why stocks with triple-digit upside potential usually come with considerable risk. A depressed stock price may reflect temporary market pessimism, but it can also signal weak earnings, high debt, slowing demand, regulatory problems, or uncertainty surrounding the company’s business model.
Analyst price targets should therefore be treated as research tools rather than guarantees. A consensus estimate showing 200% upside means analysts see significant recovery potential, but the company may still need to meet ambitious revenue, earnings, or operational expectations.
Small-Cap Valuations Remain Appealing
Morningstar Wealth believes small-cap stocks are more undervalued than they have been in years, while large-cap stocks currently appear expensive.
That valuation gap could support further gains if investors begin shifting money away from highly valued mega-cap stocks and toward smaller companies with stronger recovery potential.
Still, not every inexpensive stock will become a winner. The strongest opportunities may be found in companies with improving fundamentals, manageable debt, competitive advantages, and identifiable growth catalysts.
With that background, let’s examine the 10 stocks under $10 that could soar 200%.
CHECK THIS OUT: Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years and Top 10 Cheap Stocks Under $10 To Buy Now.
Our Methodology
In order to come up with our list of the 10 stocks under $10 that could soar 200%, we screened U.S.-listed stocks trading below $10 with market capitalizations above $2 billion, shortlisted those with at least 200% consensus upside as of the July 10 close, and ranked the 10 qualifying companies in ascending order based on their projected upside.
10 Stocks Under $10 Analysts Believe Could Soar 200%
10. Verastem Inc. (NASDAQ:VSTM)
Verastem Inc. (NASDAQ: VSTM) takes the number 10 position among the best stocks under $10 that could triple, with shares recently trading at approximately $6.06 after gaining 5.03%. The biotechnology company has attracted renewed Wall Street interest because its clinical pipeline targets difficult-to-treat cancers, including tumors driven by specific KRAS mutations.
On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ: VSTM), although the firm reduced its price target from $15 to $14. While a lower price target would normally sound discouraging, the revised estimate still represents potential upside of more than 211% from the referenced trading level. In practical terms, RBC Capital continues to see a path for Verastem Inc. (NASDAQ: VSTM) to more than triple if the company successfully advances its oncology programs and the broader biotechnology market remains supportive.
The adjustment was made as part of RBC Capital’s second-quarter biotechnology sector earnings preview. The firm pointed to improving momentum across the biotech sector during June, when biotechnology shares reportedly staged a two-week rally that outpaced the S&P 500. That strength was supported by encouraging scientific data, renewed interest in medical innovation, and more favorable investor sentiment regarding what analysts viewed as a flexible posture from the U.S. Food and Drug Administration.
This broader industry environment matters for Verastem Inc. (NASDAQ: VSTM). Development-stage biotechnology companies often depend on external financing because they may spend years funding research and clinical trials before generating meaningful product revenue. When investor sentiment toward biotech stocks improves, capital can become more accessible, merger-and-acquisition activity may increase, and companies with promising clinical assets can receive higher valuations.
RBC Capital expects capital inflows into biotechnology stocks to continue as the sector offers investors greater visibility than some other areas of the market. The firm also sees opportunities for biotechnology companies to produce stronger-than-expected second-quarter results, while ongoing pharmaceutical and biotech acquisitions could provide another layer of support. For smaller companies such as Verastem Inc. (NASDAQ: VSTM), stronger M&A activity can be particularly important because large drugmakers frequently look to acquire promising treatments, drug-development platforms, or clinical-stage assets that can strengthen their existing pipelines.
The main company-specific catalyst arrived on June 23, when Verastem Inc. (NASDAQ: VSTM) announced encouraging preliminary results from the Phase 1/2 TARGET-D 101 study evaluating VS-7375. The drug is an investigational oral inhibitor designed to target KRAS G12D mutations in patients with advanced solid tumors.
KRAS mutations have long represented one of the more difficult challenges in cancer drug development. The KRAS G12D mutation is found across several serious tumor types, creating a potentially meaningful commercial opportunity for any therapy that can safely and effectively interfere with the mutation’s role in cancer growth.
According to the preliminary findings, VS-7375 demonstrated promising clinical activity while maintaining what the company described as a manageable tolerability and safety profile across several dose levels and tumor categories. The study included patients with advanced non-small cell lung cancer, metastatic colorectal cancer, and metastatic pancreatic ductal adenocarcinoma.
These cancers represent major areas of unmet medical need. Pancreatic cancer, in particular, remains one of the most challenging malignancies to treat, while advanced lung and colorectal cancers can become resistant to existing therapies. Early signs of activity across multiple tumor types may therefore strengthen the investment case for Verastem Inc. (NASDAQ: VSTM), although investors should remember that preliminary Phase 1/2 results are not the same as definitive evidence from larger late-stage trials.
The potential attraction of VS-7375 is not limited to one disease. Because KRAS G12D mutations can appear in different cancers, successful development could eventually allow Verastem Inc. (NASDAQ: VSTM) to explore a broader range of treatment settings and combination strategies. That possibility gives the program platform-like characteristics, although considerable clinical work will still be required before its full therapeutic and commercial value can be established.
Verastem Inc. (NASDAQ: VSTM) is a development-stage biopharmaceutical company focused on developing and commercializing treatments for cancer. Its portfolio includes Avutometinib, FAKZYNJA, Defactinib, VS-7375, CO-PACK, and AVMAPKI. The company is also conducting or supporting several clinical studies, including RAMP 301, RAMP 205, FRAME, VS-7375-101, RAMP 203, and RAMP 201.
That broad pipeline gives Verastem Inc. (NASDAQ: VSTM) several potential value-creating opportunities, but it also increases the complexity and cost of development. Clinical-stage biotechnology companies must carefully manage cash, patient recruitment, regulatory communication, manufacturing preparation, and trial execution. Any delay, safety issue, disappointing efficacy result, or financing requirement could put pressure on the stock.
Nevertheless, Verastem Inc. (NASDAQ: VSTM) remains one of the more compelling biotech stocks under $10 for investors seeking exposure to precision oncology. Its substantial analyst-implied upside, encouraging early clinical activity, and portfolio of cancer drug candidates make it a speculative stock that could deliver significant returns if its most important programs continue to progress.
Click next to see the following stock...
